KCI BioTech and its wholly-owned subsidiary，KMQ BioTech are CROs specializing in preclinical efficacy and drugability evaluation for pharmaceutical R&D fields.
The company owns two AAALAC-accredited laboratory animal facilities in Suzhou and Nantong, with a total area of more than 40,000 square meters, which can meet the needs of various types of preclinical research. The company has a full range of laboratory animal platforms including mice, hamsters, guinea pigs, rabbits, cats, dogs, pigs, ferrets and non-human primates, an in vivo pharmacodynamic evaluation platform with 400+ models, an anti-infective research and development service platform, and service platforms for pathology, toxicology, pharmacokinetics, cellular and molecular biology, and medical imaging, etc. The company has already cooperated with 1,000+ famous domestic and international pharmaceutical companies, and completed 100+ projects submitted at home and abroad. We have already cooperated with 1000+ famous pharmaceutical companies at home and abroad, and completed 100+ domestic and international projects.With a professional R&D team, rich experience in in vivo pharmacology and pharmacodynamics evaluation, and a professional spirit of integrity and excellence, KCI&KMQ will provide a full range of preclinical drug discovery and development services for global pharmaceutical companies and research institutions, and establish a professional and efficient drug discovery and evaluation system!
